CANNAPHARMARX, INC. (CPMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 250K 500K 750K Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 25.8K Q2 '24: 0 Q3 '24: 312.2K Q4 '24: 482.1K Q1 '25: 335.3K Q2 '25: 231.6K Q3 '25: 656.6K Q4 '25: 138.6K Q1 '26: 627.5K Q2 '26: 276.2K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: -437.4K Q2 '24: -171.4K Q3 '24: -356.2K Q4 '24: -1.7M Q1 '25: -502.6K Q2 '25: -621.2K Q3 '25: -440K Q4 '25: -521.1K Q1 '26: -409.5K Q2 '26: -138.4K Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '16: -33.6K Q4 '16: -36.2K Q1 '17: -1.7K Q2 '17: 0 Q3 '17: 0 Q4 '17: -5K Q1 '18: 0 Q2 '18: -70.5K Q3 '18: -180.5K Q4 '18: -703.3K Q1 '19: -946.9K Q2 '19: -688.9K Q3 '19: -6.4M Q4 '19: -8M Q1 '20: -2.6M Q2 '20: -787.5K Q3 '20: -1.3M Q4 '20: -9.8M Q1 '21: -721.3K Q2 '21: -796.1K Q3 '21: -771.2K Q4 '21: -704.5K Q1 '22: -715.6K Q2 '22: -704.1K Q3 '22: -588.5K Q4 '22: -3.2M Q1 '23: -720.3K Q2 '23: -892.9K Q3 '23: -667.5K Q4 '23: 699.6K Q1 '24: -790.2K Q2 '24: -517.8K Q3 '24: -516K Q4 '24: -1.5M Q1 '25: -677.6K Q2 '25: -841K Q3 '25: -935.6K Q4 '25: -893.6K Q1 '26: -682.3K Q2 '26: -378.8K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-12M -8M -4M 0 4M 8M 12M Q3 '16: -29.5K Q4 '16: -36.2K Q1 '17: -1.7K Q2 '17: 0 Q3 '17: 0 Q4 '17: -5K Q1 '18: 0 Q2 '18: -70.5K Q3 '18: -1.1M Q4 '18: -1.9M Q1 '19: -1.1M Q2 '19: -748.1K Q3 '19: -9.3M Q4 '19: -9.3M Q1 '20: -4.2M Q2 '20: -1.5M Q3 '20: -2.7M Q4 '20: -11.6M Q1 '21: 1.2M Q2 '21: -1.7M Q3 '21: -1M Q4 '21: -7.3M Q1 '22: -2.1M Q2 '22: -1.5M Q3 '22: -1.3M Q4 '22: -3.6M Q1 '23: -1.4M Q2 '23: -1.9M Q3 '23: -564.4K Q4 '23: 7.5M Q1 '24: -11.7M Q2 '24: 5.4M Q3 '24: 188.4K Q4 '24: -3.7M Q1 '25: -690.6K Q2 '25: -1.4M Q3 '25: -1.5M Q4 '25: -7.5M Q1 '26: -382K Q2 '26: -1.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 800K 1.6M 2.4M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 463.2K Q2 '24: 171.4K Q3 '24: 668.3K Q4 '24: 2.2M Q1 '25: 837.9K Q2 '25: 852.8K Q3 '25: 1.1M Q4 '25: 659.7K Q1 '26: 1M Q2 '26: 414.7K Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q3 '16: 0 Q4 '16: -1 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: -37.8K Q3 '18: -168.5K Q4 '18: -734.9K Q1 '19: -176.5K Q2 '19: -309.9K Q3 '19: -2.3M Q4 '19: -973.4K Q1 '20: -365.7K Q2 '20: -307.7K Q3 '20: -159K Q4 '20: 268.7K Q1 '21: -799.3K Q2 '21: -256.5K Q3 '21: -1M Q4 '21: -327.3K Q1 '22: -375.2K Q2 '22: -310K Q3 '22: 328.3K Q4 '22: -1.1M Q1 '23: -611.7K Q2 '23: -482.2K Q3 '23: 123.9K Q4 '23: -1.3M Q1 '24: -548.8K Q2 '24: -427.6K Q3 '24: -540.9K Q4 '24: -179.9K Q1 '25: -601.4K Q2 '25: -446.5K Q3 '25: -802.7K Q4 '25: 1.1M Q1 '26: -243.7K Q2 '26: -127.4K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q3 '14: -491.7K Q4 '14: -784.9K Q1 '15: -649.7K Q2 '15: -822.9K Q3 '15: -737.5K Q4 '15: -340.8K Q1 '16: -17.6K Q2 '16: -4.8K Q3 '16: 0 Q4 '16: -1 Q4 '18: -734.9K Q4 '19: -975.4K Q1 '20: -365.7K Q2 '20: -307.7K Q3 '20: -159K Q4 '20: 268.7K Q1 '21: -805.6K Q2 '21: -256.5K Q3 '21: -1M Q4 '21: -327.3K Q1 '22: -391.8K Q2 '22: -354.2K Q3 '22: 282.1K Q4 '22: -1.1M Q1 '23: -612.6K Q2 '23: -556K Q3 '23: 119.7K Q4 '23: -1.3M Q1 '24: -548.8K Q4 '24: -179.9K Q4 '14 Q4 '15 Q4 '16 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 250M 500M 750M Q1 '15: 17.5M Q2 '15: 18.1M Q3 '15: 18M Q1 '16: 18M Q2 '16: 18M Q3 '16: 18M Q1 '17: 18M Q2 '17: 18M Q3 '17: 18M Q1 '18: 18M Q2 '18: 18M Q3 '18: 18M Q1 '19: 22M Q2 '19: 32.3M Q3 '19: 33.9M Q1 '20: 36.5M Q2 '20: 40M Q3 '20: 39.7M Q1 '21: 48M Q2 '21: 57.2M Q3 '21: 84.4M Q1 '22: 149.2M Q2 '22: 199.8M Q3 '22: 241.1M Q1 '23: 292.9M Q2 '23: 299.7M Q3 '23: 295.1M Q1 '24: 350.5M Q2 '24: 658M Q3 '24: 662.5M Q1 '25: 662.5M Q2 '25: 662.5M Q3 '25: 662.5M Q1 '26: 669.8M Q2 '26: 682.5M Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.75 -0.50 -0.25 0.00 0.25 0.50 0.75 Q3 '16: -0.40 Q4 '16: -0.06 Q1 '17: -0.02 Q2 '17: -0.01 Q3 '17: -0.01 Q4 '17: 0.00 Q1 '18: 0.00 Q2 '18: 0.00 Q3 '18: -0.06 Q4 '18: -0.17 Q1 '19: -0.22 Q2 '19: -0.24 Q3 '19: -0.45 Q4 '19: -0.62 Q1 '20: -0.69 Q2 '20: -0.71 Q3 '20: -0.51 Q4 '20: -0.52 Q1 '21: -0.38 Q2 '21: -0.37 Q3 '21: -0.29 Q4 '21: 0.10 Q1 '22: 0.07 Q2 '22: 0.09 Q3 '22: 0.08 Q4 '22: 0.04 Q1 '23: 0.05 Q2 '23: 0.05 Q3 '23: 0.05 Q4 '23: 0.01 Q1 '24: -0.02 Q2 '24: 0.00 Q3 '24: 0.00 Q4 '24: -0.02 Q1 '25: 0.01 Q2 '25: -0.00 Q3 '25: -0.00 Q4 '25: -0.01 Q1 '26: -0.01 Q2 '26: -0.01 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.